New cystic fibrosis drug candidate begins first human safety tests
NCT ID NCT07437105
First seen Feb 28, 2026 · Last updated May 01, 2026 · Updated 9 times
Summary
This early-stage study is testing the safety of a new drug called VX-272 in 128 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug moves through the body. The goal is to gather safety information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion - Tempe
RECRUITINGTempe, Arizona, 85283, United States
Conditions
Explore the condition pages connected to this study.